Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing FacilityGlobeNewsWire • 10/17/23
Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO ConferenceGlobeNewsWire • 09/26/23
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023GlobeNewsWire • 09/07/23
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023GlobeNewsWire • 08/31/23
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023GlobeNewsWire • 06/21/23
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023GlobeNewsWire • 06/14/23
Avid Bioservices Bolsters Manufacturing Capabilities And Generates High-Demand ServicesSeeking Alpha • 05/20/23
Avid Bioservices to Participate in RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/10/23
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future CustomersGlobeNewsWire • 04/04/23
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent DevelopmentsGlobeNewsWire • 03/13/23
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023GlobeNewsWire • 03/06/23
Avid Bioservices: Production Expansion Capex And High Costs Are Temporary IssuesSeeking Alpha • 12/09/22